Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | PPIF | P30405 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645438 | 0.81 | MAPT (0.51) | SMN1; SMN2RAB9ANPC1PKM | |
| SCHEMBL4613407 | 0.79 | ELANE (0.43) | POLBSMN1; SMN2RAB9ATDP1 | |
| SCHEMBL200043 | 0.78 | GABRA5 (0.49) | POLBSMN1; SMN2ITGA4ITGB7RAB9A | |
| SCHEMBL1403468 | 0.78 | CYP2C19 (0.55) | POLBSMN1; SMN2RAB9ANPC1PKM | |
| SCHEMBL2732414 | 0.78 | MAPT (0.48) | SMN1; SMN2RAB9ANPC1PKM | |
| SCHEMBL4615415 | 0.78 | NPC1 (0.42) | POLBSMN1; SMN2ITGA4ITGB7RAB9A | |
| SCHEMBL2728552 | 0.77 | CYP1A2 (0.47) | POLBSMN1; SMN2RAB9ANPC1TDP1 | |
| SCHEMBL2728549 | 0.77 | CYP1A2 (0.47) | POLBSMN1; SMN2RAB9ANPC1TDP1 | |
| SCHEMBL7421656 | 0.76 | ITGA4 (0.44) | ITGA4ITGB7 | |
| SCHEMBL12289156 | 0.75 | RAB9A (0.51) | ITGA4ITGB7RAB9ANPC1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | disclosed |
| CN-100361992-C | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| CN-1751044-A | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2006-03-22 | — | — | CN | disclosed |
| EP-1599477-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | disclosed |
| WO-2004074288-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | GYS2, SLC5A1, SLC5A2 | POLB 4315/4885SMN1; SMN2 1670/4885ITGA4 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.